drugset / Trial / NCT02410343

Study of TV-1106 in Growth Hormone-Deficient Adults

NCT02410343

Phase 3 Terminated 14 enrolled Teva Branded Pharmaceutical Products R&D, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to determine the efficacy of 6 months of treatment with TV-1106 compared with placebo on body fat composition.

Timeline

Start
2015-04-30
Primary completion
2015-12-31
Completion
2015-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject ALBUSOMATROPIN Protein / enzyme biologic 5 mg Subcutaneous

Indications